EyePoint Pharmaceuticals Inc (FRA:PV3B)
€ 7.932 0.038 (0.48%) Market Cap: 409.05 Mil Enterprise Value: 136.42 Mil PE Ratio: 0 PB Ratio: 1.69 GF Score: 61/100

Q2 2019 EyePoint Pharmaceuticals Inc Earnings Call Transcript

Aug 07, 2019 / 12:30PM GMT
Release Date Price: €11.03 (+1.75%)
Operator

My name is Lance, and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Second Quarter 2019 Financial Results Conference call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to Ms. Kimberly Minarovich from Argot Partners. Ma'am, you may begin.

Kimberly Minarovich
Argot Partners, LLC - MD

Thank you, Lance, and thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals' Second Quarter 2019 Financial Results and Corporate Developments.

With me today is Nancy Lurker, EyePoint's President and Chief Executive Officer; and Scott Jones, Chief Commercial Officer. Nancy and Scott will provide an overview of the recent progress made in our commercial launches as well as highlight upcoming milestones and the second quarter 2019 financial results. We will then open up the call for your questions.

Earlier this morning, we issued a press release

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot